Targets › MRPL3
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Infectious disease; next expected readout May 2027.
Open in Phaseline: the race on MRPL3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Semmelweis University | Tazobactam Bacterial beta-lactamase TEM inhibitor | MRPL3 | Phase 4 | Infection | Aug 2028 |
| Boston University | Linezolid Bacterial 70S ribosome inhibitor | MRPL3 | Phase 2 | Tuberculosis, Multidrug-Resistant | May 2027 |
Infection (1) Tuberculosis, Multidrug-Resistant (1)
small molecule (2)
Semmelweis University (1) Boston University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.